A Case Report of Biochemical Recurrent Ovarian Cancer

CHEN Shenming; CHEN Xiaofeng; XIAO Jing

Suggestions

您当前的位置：

首页 >

文章列表页 >

A Case Report of Biochemical Recurrent Ovarian Cancer

Previous: A Case of the Treatment of with Cryptogenic Organizing Pneumonia by WANG Lihua

Next: A Case of Lung Cancer Treated by Professor XIA Yuqing by Supplementing Qi and Nourishing Yin

A Case Report of Biochemical Recurrent Ovarian Cancer
1.The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510006, China
2.Departments of Gynecologic Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510006, China
DOI：

扫描看全文

CHEN Shenming, CHEN Xiaofeng, XIAO Jing. A Case Report of Biochemical Recurrent Ovarian Cancer[DB/OL].（2023-10-26）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43053465&Fpath=home&index=0
DOI：

CHEN Shenming, CHEN Xiaofeng, XIAO Jing. A Case Report of Biochemical Recurrent Ovarian Cancer[DB/OL].（2023-10-26）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43053465&Fpath=home&index=0 DOI：

摘要

病史摘要,2,女性患者，28岁，诊断为左侧卵巢中分化粘液性囊腺癌，FIGO IA期。肿瘤标志物CA 72-4在第2个化疗周期后降到正常范围，但第4个化疗周期后上升到几乎是正常上限的2倍，之后的随访期间上升到基线的7倍。CA72-4在每次升高后使用切脉针灸+中药疗法约6周后，都能恢复到基线水平。至今患者结束化疗6年，结束中药针灸治疗4年，仍在无疾病状态。这个案例强调了切脉针灸+中药治疗作为卵巢癌生化复发治疗方案的潜在效用，值得进一步研究。中医诊断　卵巢癌（脾肾阳虚，瘀热互结）西医诊断　卵巢中分化粘液性囊腺癌 IA 期干预措施　切脉针灸+中药综合治疗。疗效转归　无病生存期大于6年。

Abstract

Summary of case history,　A 28-year-old woman was diagnosed with a moderately differentiated mucinous cystadenocarcinoma of the left ovary (FIGO stage IA). The tumor marker CA 72-4 decreased to the normal range after the second cycle, but increased to almost 2 times the upper limit of normal after the fourth chemotherapy cycle, and increased to 7 times the baseline during the subsequent follow-up period. CA72-4 could return to the baseline level after about 6 weeks of acupuncture combined with Chinese medicine therapy after each rise. So far, the patient has finished chemotherapy for 6 years and completed acupuncture combine with Chinese medicine treatments for 4 years, and is still in a disease-free state. This case emphasizes the potential utility of acupuncture combine with traditional Chinese medicine as a treatment scheme for biochemical recurrence of ovarian cancer and deserves further study.,TCM diagnosis,　ovarian cancer; spleen and kidney yang deficiency, blood stasis and heat accumulation,Western medicine diagnosis,　moderately differentiated mucinous cystadenocarcinoma of ovary(FIGO stage IA),Therapeutic methods,　pulse acupuncture and traditional Chinese herbal medicine,Clinical outcomes,　disease-free survival,>,6 y,.

关键词

卵巢癌生化复发中药病例报告切脉针灸

Keywords

ovarian cancerbiochemical recurrencetraditional Chinese medicinecase reportpuls acupunctureChinese medicine

references

Hising C, Anjegard IM, Einhorn N. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients[J]. Am J Clin Oncol. 1991;14:111–4.

Tuxen MK, Soletormos G, Dombernowsky P. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up[J]. Scand J Clin Lab Invest. 2002;62:177–88.

Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer: a randomised trial[J].Lancet 2010,376:1155-1163.

Kristeleit R, Davidenko I, Shirinkin V, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer[J]. Gynecol Oncol. 2017;146(3):484-490.

Wang Z, Huang Y, Long L, et al. Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression[J]. J Ovarian Res. 2021;14(1):91.

陈小凤,肖静,俞云.俞云切脉针灸对生化复发型卵巢癌的针药结合治疗心得[J].时珍国医国药,2019,30(2):474-476.

Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer[J]. N Engl J Med, 2019, 381(25): 2416-2428.

Penson R T, Valencia R V, Cibula D, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial[J]. J Clin Oncol, 2020, 38(11): 1164-1174.

Vetter M HHays J L. Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions[J]. Clin Ther, 2018, 40(3): 361-371.

俞云.切脉针灸治癌[M].合肥: 安徽科学技术出版社,1994.

俞云.切脉针灸－黄帝内经针法[M].北京: 人民卫生出版社,2013.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A Case Report of SCC Increased After Treatment of Cervical Squamous Cell Cancer

One Case of Ovarian Cancer Biochemical Recurrence Treated by Wenyang Huaji Method

Analysis of Treating Kidney Disease with Triplet Drugs of Professor RUAN Shiwei

A Case Report of Traditional Chinese Medicine in the Treatment of Intrauterine Adhesions

A Case of Erythroderma in Children Treated from Spot Due to Yang Ming

Related Author

No data

Related Institution

Department of Oncology, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital

Department of Oncology, Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University

People's Hospital Affiliated to Fujian University of Chinese Medicine Nephrdogy

Fujian University of Chinese Medicine

(Department of Obstetrics and Gynecology, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, , )

⁰